AU1537292A
(en)
*
|
1991-04-16 |
1992-11-17 |
Nippon Shinyaku Co. Ltd. |
Method of manufacturing solid dispersion
|
US5567439A
(en)
*
|
1994-06-14 |
1996-10-22 |
Fuisz Technologies Ltd. |
Delivery of controlled-release systems(s)
|
DE19509805A1
(de)
*
|
1995-03-21 |
1996-09-26 |
Basf Ag |
Transparente, schnell freisetzende Zubereitungen von nichtsteroidalen Analgetica
|
DE19602206A1
(de)
|
1996-01-23 |
1997-07-24 |
Basf Ag |
Zubereitungen nichtsteroidaler Analgetika
|
US6139872A
(en)
*
|
1996-08-14 |
2000-10-31 |
Henkel Corporation |
Method of producing a vitamin product
|
DE19733505A1
(de)
|
1997-08-01 |
1999-02-04 |
Knoll Ag |
Schnell wirksames Analgeticum
|
EP1137403B1
(en)
|
1998-12-11 |
2009-03-11 |
Nostrum Pharmaceuticals, Inc. |
Sustained release tablet containing hydrocolloid and cellulose ether
|
DE19901040A1
(de)
*
|
1999-01-14 |
2000-07-20 |
Knoll Ag |
Arzneiformen mit gesteuerter Freisetzung, enthaltend gut wasserlösliche Wirkstoffe
|
DE19933289A1
(de)
*
|
1999-07-15 |
2001-01-18 |
Basf Ag |
Verfahren zur Herstellung eines Granulats aus einer Schmelze
|
US6327354B1
(en)
*
|
1999-08-17 |
2001-12-04 |
Ameritech Corporation |
Methods, systems, and articles for providing a family telecommunication service
|
DE19945982A1
(de)
*
|
1999-09-24 |
2001-03-29 |
Knoll Ag |
Geschwindigkeitsbestimmte Partikel
|
ATE316781T1
(de)
*
|
1999-09-24 |
2006-02-15 |
Janssen Pharmaceutica Nv |
Antivirale feste dispersionen
|
US6264981B1
(en)
†
|
1999-10-27 |
2001-07-24 |
Anesta Corporation |
Oral transmucosal drug dosage using solid solution
|
WO2001034119A2
(en)
*
|
1999-11-12 |
2001-05-17 |
Abbott Laboratories |
Inhibitors of crystallization in a solid dispersion
|
US7364752B1
(en)
|
1999-11-12 |
2008-04-29 |
Abbott Laboratories |
Solid dispersion pharamaceutical formulations
|
DE10026698A1
(de)
*
|
2000-05-30 |
2001-12-06 |
Basf Ag |
Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
|
GB0102342D0
(en)
|
2001-01-30 |
2001-03-14 |
Smithkline Beecham Plc |
Pharmaceutical formulation
|
US7883721B2
(en)
|
2001-01-30 |
2011-02-08 |
Smithkline Beecham Limited |
Pharmaceutical formulation
|
US7842308B2
(en)
|
2001-01-30 |
2010-11-30 |
Smithkline Beecham Limited |
Pharmaceutical formulation
|
US20050175687A1
(en)
*
|
2001-01-30 |
2005-08-11 |
Mcallister Stephen M. |
Pharmaceutical formulations
|
US20040015519A1
(en)
*
|
2001-10-15 |
2004-01-22 |
Yukitoshi Maeda |
Content delivery server and content delivery system having the same
|
US7050559B2
(en)
*
|
2001-12-21 |
2006-05-23 |
Bellsouth Intellectual Property Corporation |
Monitoring a call forwarded to a network-based voice mail system
|
US7776314B2
(en)
|
2002-06-17 |
2010-08-17 |
Grunenthal Gmbh |
Abuse-proofed dosage system
|
ATE442130T1
(de)
|
2002-08-12 |
2009-09-15 |
Bend Res Inc |
Arzneizubereitungen bestehend aus arzneimitteln in halb-geordneter form und polymeren
|
BRPI0407181A
(pt)
*
|
2003-02-03 |
2006-02-07 |
Novartis Ag |
Formulação farmacêutica
|
AU2003304242A1
(en)
*
|
2003-06-27 |
2005-01-13 |
Bioprogress S.P.A. |
Composite product obtainable by cogrinding of a active principle with a copolymer n-vinyl-2-pyrrolidone/vinyl-acetate
|
TW200526274A
(en)
|
2003-07-21 |
2005-08-16 |
Smithkline Beecham Plc |
Pharmaceutical formulations
|
DE102004020220A1
(de)
*
|
2004-04-22 |
2005-11-10 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
|
DE102005005446A1
(de)
*
|
2005-02-04 |
2006-08-10 |
Grünenthal GmbH |
Bruchfeste Darreichungsformen mit retardierter Freisetzung
|
DE10336400A1
(de)
|
2003-08-06 |
2005-03-24 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte Darreichungsform
|
DE102004032051A1
(de)
|
2004-07-01 |
2006-01-19 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
|
US20070048228A1
(en)
|
2003-08-06 |
2007-03-01 |
Elisabeth Arkenau-Maric |
Abuse-proofed dosage form
|
ES2407143T3
(es)
*
|
2003-08-06 |
2013-06-11 |
Grünenthal GmbH |
Forma de dosificación protegida contra un posible abuso
|
DE10361596A1
(de)
|
2003-12-24 |
2005-09-29 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
|
US8075872B2
(en)
|
2003-08-06 |
2011-12-13 |
Gruenenthal Gmbh |
Abuse-proofed dosage form
|
US8025899B2
(en)
*
|
2003-08-28 |
2011-09-27 |
Abbott Laboratories |
Solid pharmaceutical dosage form
|
US8377952B2
(en)
*
|
2003-08-28 |
2013-02-19 |
Abbott Laboratories |
Solid pharmaceutical dosage formulation
|
WO2005053652A1
(en)
|
2003-12-04 |
2005-06-16 |
Pfizer Products Inc. |
Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
|
BRPI0416534A
(pt)
*
|
2003-12-04 |
2007-01-09 |
Pfizer Prod Inc |
composições multiparticuladas com estabilidade melhorada
|
EP1691787B1
(en)
*
|
2003-12-04 |
2008-07-02 |
Pfizer Products Inc. |
Method for making pharmaceutical multiparticulates
|
WO2005053653A1
(en)
*
|
2003-12-04 |
2005-06-16 |
Pfizer Products Inc. |
Spray-congeal process using an extruder for preparing multiparticulate azithromycin compositions containing preferably a poloxamer and a glyceride
|
US6984403B2
(en)
*
|
2003-12-04 |
2006-01-10 |
Pfizer Inc. |
Azithromycin dosage forms with reduced side effects
|
WO2005053639A2
(en)
*
|
2003-12-04 |
2005-06-16 |
Pfizer Products Inc. |
Controlled release multiparticulates formed with dissolution enhancers
|
CA2549225A1
(en)
*
|
2003-12-04 |
2005-06-16 |
Pfizer Products Inc. |
Spray-congeal process using an extruder for preparing multiparticulate crystalline drug compositions containing preferably a poloxamer and a glyceride
|
RU2006119453A
(ru)
*
|
2003-12-04 |
2007-12-20 |
Пфайзер Продактс Инк. (Us) |
Получение посредством основанных на применении жидкостей способов лекарственные формы азитромицина с большим количеством частиц
|
TW201240679A
(en)
*
|
2004-03-12 |
2012-10-16 |
Capsugel Belgium Nv |
Pharmaceutical formulations
|
WO2005123052A1
(fr)
*
|
2004-06-18 |
2005-12-29 |
Jiangsu Hengrui Medicine Co., Ltd. |
Composition medicamenteuse contenant de l'ambroxol et de l'erdosteine ou de l'acetylcysteine
|
DE102004032103A1
(de)
*
|
2004-07-01 |
2006-01-19 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte, orale Darreichungsform
|
DE102004032049A1
(de)
|
2004-07-01 |
2006-01-19 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte, orale Darreichungsform
|
KR101086254B1
(ko)
*
|
2004-11-04 |
2011-11-24 |
에스케이케미칼주식회사 |
생체이용률이 개선된 프란루카스트 고체분산체 조성물 및그 고체분산체의 제조방법
|
DE102005005449A1
(de)
|
2005-02-04 |
2006-08-10 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
|
EP1800667A1
(en)
|
2005-12-23 |
2007-06-27 |
Losan Pharma GmbH |
Rapidly solubilizing ibuprofen granulate
|
US9205054B2
(en)
*
|
2005-03-22 |
2015-12-08 |
Losan Pharma Gmbh |
Solubilized ibuprofen
|
KR101374928B1
(ko)
*
|
2005-11-09 |
2014-03-14 |
노파르티스 아게 |
일시적 가소제를 사용한 약학 조성물의 제조 방법
|
WO2007069874A1
(en)
*
|
2005-12-16 |
2007-06-21 |
Hanmi Pharm. Co., Ltd. |
Solid dispersion comprising an active ingredient having a low melting point and tablet for oral administration comprising same
|
WO2008067164A2
(en)
*
|
2006-11-15 |
2008-06-05 |
Abbott Laboratories |
Solid pharmaceutical dosage formulations
|
DE102007011485A1
(de)
|
2007-03-07 |
2008-09-11 |
Grünenthal GmbH |
Darreichungsform mit erschwertem Missbrauch
|
JP2011503048A
(ja)
|
2007-11-08 |
2011-01-27 |
グラクソ グループ リミテッド |
医薬製剤
|
MX2010007645A
(es)
*
|
2008-01-11 |
2010-11-05 |
Cipla Ltd |
Forma de dosis farmaceutica solida.
|
BRPI0906467C1
(pt)
|
2008-01-25 |
2021-05-25 |
Gruenenthal Gmbh |
forma de dosagem farmacêutica com formato exterior modificado resistente à ruptura e com liberação controlada
|
LT2273983T
(lt)
|
2008-05-09 |
2016-10-25 |
Grünenthal GmbH |
Tarpinės miltelių kompozicijos gamybos būdas ir galutinė kieta dozavimo forma naudojant purškalo kietinimo stadija
|
AU2009256572A1
(en)
*
|
2008-06-13 |
2009-12-17 |
Capsugel Belgium Nv |
Hydroxypropyl cellulose capsule shell
|
US8041893B1
(en)
|
2008-09-09 |
2011-10-18 |
Vignette Software Llc |
System and method for managing large filesystem-based caches
|
US20100137443A1
(en)
|
2008-09-10 |
2010-06-03 |
Biochemics, Inc. |
Ibuprofen for Topical Administration
|
US9566256B2
(en)
|
2008-09-22 |
2017-02-14 |
Biochemics, Inc. |
Transdermal drug delivery using an osmolyte and vasoactive agent
|
TW201105316A
(en)
|
2009-07-22 |
2011-02-16 |
Gruenenthal Gmbh |
Hot-melt extruded pharmaceutical dosage form
|
KR101747156B1
(ko)
|
2009-07-22 |
2017-06-27 |
그뤼넨탈 게엠베하 |
산화-안정화된 탬퍼-내성 용량형
|
CN102821757B
(zh)
*
|
2010-02-03 |
2016-01-20 |
格吕伦塔尔有限公司 |
通过挤出机制备粉末状药物组合物
|
RU2607499C2
(ru)
|
2010-09-02 |
2017-01-10 |
Грюненталь Гмбх |
Устойчивая к разрушению лекарственная форма, которая содержит анионный полимер
|
MX2013002377A
(es)
|
2010-09-02 |
2013-04-29 |
Gruenenthal Gmbh |
Forma de dosificacion resistente a manipulacion que comprende una sal inorganica.
|
US9744132B2
(en)
|
2010-10-29 |
2017-08-29 |
Infirst Healthcare Limited |
Solid solution compositions and use in chronic inflammation
|
US9308213B2
(en)
|
2010-10-29 |
2016-04-12 |
Infirst Healthcare Limited |
Solid solution compositions and use in chronic inflammation
|
US11202831B2
(en)
|
2010-10-29 |
2021-12-21 |
Infirst Healthcare Limited |
Solid solution compositions and use in cardiovascular disease
|
US11730709B2
(en)
|
2010-10-29 |
2023-08-22 |
Infirst Healthcare Limited |
Compositions and methods for treating severe pain
|
US11224659B2
(en)
|
2010-10-29 |
2022-01-18 |
Infirst Healthcare Limited |
Solid solution compositions and use in severe pain
|
BR112013021030A2
(pt)
|
2011-02-17 |
2016-10-11 |
Hoffmann La Roche |
processo para cristalização controlada de um ingrediente farmacêutico ativo a partir de estado líquido super-refrigerado por extrusão por fusão a quente
|
EA201400173A1
(ru)
|
2011-07-29 |
2014-06-30 |
Грюненталь Гмбх |
Устойчивая к разрушению таблетка, которая обеспечивает немедленное высвобождение лекарственного средства
|
EA201400172A1
(ru)
|
2011-07-29 |
2014-06-30 |
Грюненталь Гмбх |
Устойчивая к разрушению таблетка, которая обеспечивает немедленное высвобождение лекарственного средства
|
JP6117249B2
(ja)
|
2012-02-28 |
2017-04-19 |
グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング |
薬理学的に活性な化合物および陰イオン性ポリマーを含むタンパーレジスタント剤形
|
JP6282261B2
(ja)
|
2012-04-18 |
2018-02-21 |
グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング |
不正使用防止および過量放出防止医薬剤形
|
US10064945B2
(en)
|
2012-05-11 |
2018-09-04 |
Gruenenthal Gmbh |
Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
|
AU2014273227B2
(en)
|
2013-05-29 |
2019-08-15 |
Grunenthal Gmbh |
Tamper-resistant dosage form containing one or more particles
|
AR096439A1
(es)
|
2013-05-29 |
2015-12-30 |
Gruenenthal Gmbh |
Forma de dosificación resistente al uso indebido que contiene una o más partículas
|
CA2917136C
(en)
|
2013-07-12 |
2022-05-31 |
Grunenthal Gmbh |
Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
|
JP6480936B2
(ja)
|
2013-11-26 |
2019-03-13 |
グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング |
クライオミリングによる粉末状医薬組成物の調製
|
UY36046A
(es)
|
2014-03-26 |
2015-10-30 |
Millennium Pharm Inc |
Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
|
AU2015261060A1
(en)
|
2014-05-12 |
2016-11-03 |
Grunenthal Gmbh |
Tamper resistant immediate release capsule formulation comprising Tapentadol
|
EA201692388A1
(ru)
|
2014-05-26 |
2017-05-31 |
Грюненталь Гмбх |
Лекарственная форма в виде множества частиц, защищенная от вызываемого этанолом сброса дозы
|
GB201502077D0
(en)
*
|
2015-02-09 |
2015-03-25 |
Cubic Pharmaceuticals Ltd And Delta Pharmaceuticals Ltd |
Improved hme technology
|
WO2016128235A1
(en)
*
|
2015-02-11 |
2016-08-18 |
Nestec S.A. |
Vitamin a composition
|
MX2017013637A
(es)
|
2015-04-24 |
2018-03-08 |
Gruenenthal Gmbh |
Forma de dosificacion resistente a alteraciones con liberacion inmediata y resistencia contra la extraccion por solventes.
|
CA2998259A1
(en)
|
2015-09-10 |
2017-03-16 |
Grunenthal Gmbh |
Protecting oral overdose with abuse deterrent immediate release formulations
|